Powersravn9710
Ovarian cancer (OC) is a serious threat to women's life. OC is insidious and lacks early diagnosis and effective treatment. Therefore, it is vital to look for new therapeutic targets and biomarkers.
MicroRNA-877 (miR-877) expression level in OC was accessed via quantitative real-time polymerase chain reaction (qRT-PCR). Transwell assay, Matrigel assay and wound healing assay were used to analyze the ability of miR-877 on cell migration and invasion. Luciferase reporter assay was employed for verification the target of miR-877. Western blotting was taken in for the determination of the expression level of FOXM1.
MiR-877 had low expression level in OC tissues and cell lines. MiR-877 over-expression induced inhibition of cell migration and invasion. this website FOXM1 was a direct target of miR-877. MiR-877 restrained cell migration and invasion by negatively regulating FOXM1 expression in OC.
Our research elucidated that miR-877 played a role of tumor suppressor in OC by negatively regulating FOXM1 which may bring a novel insight into new molecular therapeutic targets and biomarkers for OC.
Our research elucidated that miR-877 played a role of tumor suppressor in OC by negatively regulating FOXM1 which may bring a novel insight into new molecular therapeutic targets and biomarkers for OC.
This study initially explored the expression of GDF-15 in gallbladder carcinoma and its clinical significance, and analyzed the correlation between the expression of GDF-15 and the clinicopathological features as well as the prognosis of patients with gallbladder carcinoma.
Enzyme-linked immunosorbent assay (ELISA) was used to determine the expression of GDF-15 in the serum of 42 patients with gallbladder cancer. The control group included 24 patients with cholecystitis and 20 healthy volunteers. The immunohistochemical method (IHC) was used to detect the expression of GDF-15 in 42 cases of gallbladder tumor tissue and 35 cases of adjacent non-tumor gallbladder tissue specimens.
The results of ELISA showed that the concentration of GDF-15 in serum was considerably higher in gallbladder cancer patients than that in gallbladder benign lesions and healthy volunteers (p=0.006, p<0.001). In the group of patients with gallbladder cancer, the consistence of GDF-15 in patients with lymph node metastasis was significantly higher than that of patients without lymph node metastasis (p<0.001). Immunohistochemical staining showed that the expression of GDF-15 in gallbladder carcinoma was markedly higher than that in non-tumor gallbladder tissues (p=0.003), and the high expression of GDF-15 was significantly correlated with the differentiation grade of gallbladder carcinoma and tumor TNM stage (p=0.005, p=0.002).
GDF-15 is related to the occurrence and development of gallbladder cancer. GDF-15 in serum can be used as a potential marker for the diagnosis of gallbladder cancer and can be used to predict the lymph node metastasis of gallbladder cancer.
GDF-15 is related to the occurrence and development of gallbladder cancer. GDF-15 in serum can be used as a potential marker for the diagnosis of gallbladder cancer and can be used to predict the lymph node metastasis of gallbladder cancer.
To explore the effectiveness and safety of conversion surgery after neoadjuvant intraperitoneal-systemic chemotherapy (NIPS) in treating gastric cancer patients with peritoneal metastasis.
80 patients definitely diagnosed with peritoneal metastasis of gastric cancer treated in our hospital from March 2016 to September 2017 were evaluated. All the patients were randomly assigned into two groups and received oral administration of S-1 + intravenous and intraperitoneal chemotherapy with paclitaxel or oral administration of S-1 + intravenous chemotherapy with oxaliplatin, with 40 patients in each group. Following NIPS conversion therapy, the patients with indications for surgery underwent radical gastrectomy. link2 The short-term efficacy of chemotherapy and incidence of chemotherapy-related adverse reactions were compared between the two groups. link3 The surgical methods, intraoperative conditions (lymph node dissection and surgical margins) and postoperative complications were recorded in the two groups of patients, aival (mOS) was 13.4 months in NIPS group and 10.8 months in control group.
NIPS combined with radical gastrectomy has definite efficacy in treating gastric cancer patients with peritoneal metastasis and cause tolerable adverse reactions, and it can significantly raise the patient survival compared with systemic chemotherapy alone.
NIPS combined with radical gastrectomy has definite efficacy in treating gastric cancer patients with peritoneal metastasis and cause tolerable adverse reactions, and it can significantly raise the patient survival compared with systemic chemotherapy alone.
Perioperative enteral nutrition supports are recommended in esophagus cancer patients. Immunonutrition contains immuno-enhancing nutrients in addition to standard formula. These new nutrients are thought to be efficacious in reducing inflammatory response and improving postoperative immune response and they have been proved to be better than standard enteral nutrition in reducing postoperative complications in gastric cancer. However, if it would lead to a better clinical outcome in patients undergoing esophagectomy remains controversial.
A systematic literature search was performed in the online database of PubMed, Medline, EMBASE and Cochrane Library. The relevant studies were screened out of the results by reading titles and abstracts. Then, we read the full-texts to finally confirm the studies included in this meta-analysis.
Six randomized controlled trials having enrolled 638 patients were included in the final analysis. The pooled analysis didn't show statistically significant difference between immunonutrition group and standard nutrition group in reducing postoperative complications.
The postoperative complications are comparable between immunonutrition and the standard enteral nutrition in patients undergoing esophagectomy, but its value in severe malnutrition patients is undetermined, whereas the high tolerance and other advantages brought by the immunonutrition should not be overlooked and need to be further proved.
The postoperative complications are comparable between immunonutrition and the standard enteral nutrition in patients undergoing esophagectomy, but its value in severe malnutrition patients is undetermined, whereas the high tolerance and other advantages brought by the immunonutrition should not be overlooked and need to be further proved.
The purpose of this study was to compare the multifocal (MF)/multicentric (MC) breast cancers with unifocal (UF) breast cancers in terms of tumour characteristics, treatment methods, loco-regional recurrence and survival rates.
Patients who were treated with a diagnosis of early-stage breast cancer (stage I,II) and had regular follow-up were included in the study. MF tumours were defined as having more than one tumour focus in the same quadrant, whereas MC tumours refered to the presence of more than one tumour focus in different quadrants.
In total, 1865 patients with invasive breast cancer were evaluated, 1493 (80.1%) of whom had UF cancer, 330 (17.7%) had MF cancer, and 42 (2.3%) had MC cancer. After comparing the groups with each other, it was seen that MF and MC breast cancers occurred more often at early ages and that lymph node invasion (LNI) was greater. No differences were seen between the 3 groups in terms of local recurrence-free survival (RFS) and overall survival (OS) rates . In multivariate analysis, it was found that MF and MC tumours had no impact on local recurrence and OS. In multivariate analysis, it was understood that HER2 positivity and triple-negative breast cancer (TNBC) had an impact on local recurrence, and age, lymphovascular invasion (LVI), T3 tumour, lymph node positivity and TNBC subtype had an impact on OS.
Although MC and MF tumours show aggressive features such as high lymph node positivity and LVI, they have similar loco-regional recurrence and survival rates to UF tumours.
Although MC and MF tumours show aggressive features such as high lymph node positivity and LVI, they have similar loco-regional recurrence and survival rates to UF tumours.
To explore the efficacy and safety of 500 mg of fulvestrant for the postmenopausal patients with estrogen receptor (ER)-positive metastatic breast cancer, and to analyze the factors affecting the prognosis of patients.
A retrospective analysis was conducted on the clinical data of 86 postmenopausal patients with ER-positive metastatic breast cancer, who were admitted to our hospital from January 2015 to December 2016, and these patients were treated with 500 mg of fulvestrant. The clinical efficacy and incidence of adverse reactions were evaluated. Moreover, the patients were followed up for recording the survival and disease progression. Finally, survival analysis was carried out using the Kaplan-Meier method, log-rank test and Cox's proportional hazards regression model.
Among the 86 patients, 7 achieved partial response (PR), with an objective response rate (ORR) of 8.1%, and 44 (51.2%) had stable disease (SD), including 21 cases of SD ≥24 weeks, and the clinical benefit rate (CBR) [proportion of caswhile it notably extends the mPFS of patients who have no visceral metastasis and receive no prior tamoxifen or endocrine therapy, but the first-line fulvestrant therapy in this study.
Fulvestrant has definite efficacy in treating ER-positive metastatic breast cancer and results in tolerable adverse reactions, while it notably extends the mPFS of patients who have no visceral metastasis and receive no prior tamoxifen or endocrine therapy, but the first-line fulvestrant therapy in this study.
To investigate the effects of micro ribonucleic acid (miR)-125b on the growth and apoptosis of malignant melanoma (MM) cells and related mechanisms.
The differences in the expressions of miR-125b and neural cell adhesion molecule-120 (NCAM-120), NCAM-140 and NCAM-180 in 5 cases of MM tissues (MM group) and corresponding adjacent tissues (Paracancer group) as well as MM cells were detected via quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry, respectively. Next, malignant melanoma A375 cells were selected to exogenously overexpress miR-125 (miR-125 mimic group). Then, in vitro functional assays were conducted to determine the influences of miR-125b on the proliferation, migration and apoptosis of MM cells, and the changes in the binding of miR-125b to the 3'-untranslated region (3'-UTR) of wild-type and mutant NCAM messenger RNAs (mRNAs) were verified using dual-luciferase assay.
MiR-125b was significantly lowly expressed in MM tissues and cells (p<0.01), while NCAM-120, NCAM-140 and NCAM-180 were clearly highly expressed in MM tissues and cells (p<0.05). After miR-125b was exogenously overexpressed in A375 cells, the proliferation and migration ability of A375 cells was decreased, whereas the proportion of apoptotic cells rose (p<0.05). Besides, the results of dual-luciferase reporter assay revealed that the luciferase activity of A375 cells in the 3'-UTR of wild-type NCAM mRNA was overtly lowered compared with that of mutant NCAM mRNA (p<0.05).
MiR-125b acts as a tumor suppressor in MM cells by targeting and binding to NCAM.
MiR-125b acts as a tumor suppressor in MM cells by targeting and binding to NCAM.
